Retro Biosciences
retro.bio
Actively hiring
Drug Discovery
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
67
US Form 5500 (plan participants) · Dec 2025 · +5% in a year
Hiring now
5
+1 posted in 30 days
Momentum
8/100
hiring for its size
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jun 2021
Website went live first capture in the Wayback Machine
Tractionpublic signals, read monthly
Web presence
top 6%
of 133.2M domains by links, Common Crawl
Hacker News stories
1
best: 1 points
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent…
Anivance AI（久浪智醫）— 以器官晶片與 AI 驅動新一代藥物開發。Physical AI infrastructure for human biology through organ-on-chip systems, laboratory automation…
TenSixty Biosciences expands the druggable oncology universe through epitope-level targeting and a biology-first therapeutic discovery…
Defining a new era in drug discovery where chemistry rewrites the rules of biology to engage any protein target.
Zymedi leverages ARS biology to discover novel therapeutics and first-in-class drugs for patients.
Transforming biology from empirical to. Frontier AI lab training the first scientific poly-intelligence to read all the layers of biology…
News
Sam Altman's longevity startup is testing a pill for a younger brain
Retro Biosciences is set to run a clinical trial for an aging drug designed to reverse Alzheimer's, its CEO Joe Betts-LaCroix, told Business Insider.
Read more
Report
Sam Altman-Backed Startup Aims to Add 10 Years to Human Life Through Stem Cell Tech
Retro Biosciences, a longevity startup funded by OpenAI's Sam Altman, hopes that blood stem cell research will aid in anti-aging efforts.
Read more
Report
Retro Biosciences, backed by Sam Altman, is raising $1 billion to extend human lifespan
OpenAI CEO Sam Altman is doubling down on Retro Biosciences, a biotech startup based in San Francisco that wants humans to live 10 years longer than what it calls a healthy human lifespan. Now, the startup is raising a $1 billion Series A that Altman is j
Read more
Report
Joe Betts-Lacroix from Retro.bio on the power of AI to shorten the path to transformative longevity
Podcast Episode In the Know with Amol Sarva July 10, 2023 53m
Read more
Report
Sam Altman invested $180 million into a company trying to delay death
Can anti-aging breakthroughs extend the human lifespan? The CEO of OpenAI is paying to find out.
Read more
Report
Salary insights
Compensation ranges based on this company's open jobs
Median
$210k
Typical range
$95k – $280k
Open positions
5
4
Jobs
Senior
50%
Staff
25%
Architect
25%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Senior | 2 | $180k | $150k – $210k |
| Staff | 1 | $260k | $260k |
| Architect | 1 | $280k | $280k |
Highest paying role
Head of Quality, Cell Therapy
$280k
Normalized to USD per year
All salaries at Retro Biosciences
By role, level and city, against the market · 5 jobs with pay
Growth
Hiring Momentum
23/100
Hiring freeze
Open positions
5
0 opened / 0 closed in 30 days
Median time-to-fill
75 days
faster than 18% of the market
ATS activity
Every ~4 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Science & Research
75% ▲
Field & Service
25% ▼
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Redwood City
Redwood City
United States
HQ
6 open roles 4 posted in 90 days 50% engineering 50-200 est. staff $199k Avg Salary
hires for Science & Research, Public Policy, Field & Service